Mouwasat Medical Services Company

SASE:4002 Stock Report

Market Cap: ر.س15.2b

Mouwasat Medical Services Valuation

Is 4002 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4002 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
ر.س67.88
Fair Value
12.0% overvalued intrinsic discount
14
Number of Analysts

Below Fair Value: 4002 (SAR76) is trading above our estimate of fair value (SAR67.88)

Significantly Below Fair Value: 4002 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4002?

Key metric: As 4002 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4002. This is calculated by dividing 4002's market cap by their current earnings.
What is 4002's PE Ratio?
PE Ratio22.6x
Earningsر.س671.23m
Market Capر.س15.18b

Price to Earnings Ratio vs Peers

How does 4002's PE Ratio compare to its peers?

The above table shows the PE ratio for 4002 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.6x
4004 Dallah Healthcare
23.7x13.45%ر.س11.9b
4017 Dr. Soliman Abdel Kader Fakeeh Hospital
36x14.69%ر.س10.3b
4005 National Medical Care
24.4x11.59%ر.س7.4b
4018 Almoosa Health
54.4x25.65%ر.س7.2b
4002 Mouwasat Medical Services
22.6x11.89%ر.س15.2b

Price-To-Earnings vs Peers: 4002 is good value based on its Price-To-Earnings Ratio (22.6x) compared to the peer average (34.6x).

Price to Earnings Ratio vs Industry

How does 4002's PE Ratio compare vs other companies in the SA Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4002 22.6xIndustry Avg. 24.3xNo. of Companies4PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4002 is good value based on its Price-To-Earnings Ratio (22.6x) compared to the SA Healthcare industry average (24.4x).

Price to Earnings Ratio vs Fair Ratio

What is 4002's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4002 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.6x
Fair PE Ratio26.9x

Price-To-Earnings vs Fair Ratio: 4002 is good value based on its Price-To-Earnings Ratio (22.6x) compared to the estimated Fair Price-To-Earnings Ratio (26.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4002 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س76.00
ر.س97.14
+27.81%
17.11%ر.س132.00ر.س75.00n/a14
May ’26ر.س72.30
ر.س97.13
+34.35%
18.01%ر.س132.00ر.س75.00n/a12
Apr ’26ر.س75.00
ر.س104.33
+39.10%
16.63%ر.س134.20ر.س77.00n/a14
Mar ’26ر.س84.60
ر.س117.41
+38.78%
12.83%ر.س145.00ر.س92.30n/a14
Feb ’26ر.س92.10
ر.س117.34
+27.40%
12.82%ر.س145.00ر.س92.30n/a14
Jan ’26ر.س85.80
ر.س119.65
+39.45%
11.72%ر.س145.00ر.س92.30n/a14
Dec ’25ر.س91.00
ر.س123.29
+35.49%
10.51%ر.س145.00ر.س92.30n/a14
Nov ’25ر.س94.10
ر.س123.72
+31.47%
10.77%ر.س145.00ر.س90.80n/a12
Oct ’25ر.س100.00
ر.س124.33
+24.33%
10.90%ر.س145.00ر.س90.20n/a12
Sep ’25ر.س106.20
ر.س125.75
+18.41%
12.22%ر.س152.00ر.س90.20n/a12
Aug ’25ر.س117.00
ر.س132.52
+13.26%
10.61%ر.س152.00ر.س96.90n/a11
Jul ’25ر.س120.00
ر.س128.39
+6.99%
12.70%ر.س152.00ر.س96.90n/a12
Jun ’25ر.س107.00
ر.س127.48
+19.14%
11.92%ر.س146.00ر.س96.90n/a12
May ’25ر.س134.00
ر.س126.38
-5.68%
12.40%ر.س146.00ر.س96.90ر.س72.3013
Apr ’25ر.س136.80
ر.س120.50
-11.92%
14.73%ر.س146.00ر.س74.40ر.س75.0013
Mar ’25ر.س123.40
ر.س119.31
-3.32%
14.72%ر.س145.00ر.س71.30ر.س84.6012
Feb ’25ر.س120.20
ر.س117.06
-2.61%
14.81%ر.س145.00ر.س71.30ر.س92.1012
Jan ’25ر.س114.80
ر.س113.99
-0.70%
13.50%ر.س132.50ر.س71.30ر.س85.8012
Dec ’24ر.س112.60
ر.س112.31
-0.26%
13.01%ر.س132.50ر.س71.30ر.س91.0011
Nov ’24ر.س98.00
ر.س111.98
+14.27%
13.64%ر.س132.50ر.س68.70ر.س94.1011
Oct ’24ر.س106.00
ر.س113.05
+6.66%
12.99%ر.س132.50ر.س71.00ر.س100.0011
Sep ’24ر.س110.20
ر.س114.87
+4.24%
13.42%ر.س132.50ر.س71.00ر.س106.2011
Aug ’24ر.س126.50
ر.س114.60
-9.41%
13.43%ر.س132.50ر.س72.50ر.س117.0010
Jul ’24n/a
ر.س114.60
0%
13.43%ر.س132.50ر.س72.50ر.س120.0010
Jun ’24ر.س111.00
ر.س112.11
+1.00%
13.34%ر.س130.00ر.س72.50ر.س107.009
May ’24ر.س125.60
ر.س113.40
-9.71%
15.66%ر.س135.00ر.س65.00ر.س134.0010
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
ر.س97.14
Fair Value
21.8% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 08:56
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mouwasat Medical Services Company is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ibrahim ElaiwatAljazira Capital Company
Jassim Al-JubranAljazira Capital Company
Rim Ben Salah GharbiAlphaMena